| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 2.04 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Metabolic syndrome (MS) is recognized as a risk factor for colon cancer (CC). However, how does the interplay between metabolic dysfunction caused by MS and its individual components affect CC microenvironment and prognosis remains unexplored. Angiogenesis and lymphangiogenesis are fundamental processes for tumor progression and dissemination, ensuring oxygen and nutrient delivery and supporting one of the most important pathways of tumor dissemination, contributing to metastasis. Thus, our aim was to evaluate whether the expression of molecular biomarkers involved in angiogenic and lymphangiogenic processes influenced CC clinicopathological features and prognosis in patients with MS. Clinical and pathological data of 300 patients submitted to CC surgical resection at a single tertiary hospital were retrospectively retrieved from hospital records. Tumor tissue microarrays of archived paraffin-embedded blocks were used to assess CD31, VEGF-A and D2–40 tissue expression by immunohistochemistry. The percentage of stained area was quantified by computerized morphometric analysis. No association between tissue expression of angiogenesis and lymphangiogenesis biomarkers and tumor clinical and pathological characteristics was found. However, in subgroup analysis of patients with MS, dysglycemia was associated with lower D2–40 expression (p = 0.007) and high waist-circumference was associated with higher D2–40 (p = 0.0029) and VEGF-A expression (p = 0.026). In an adjusted Cox proportional hazard model CD31 expression was significantly associated with greater disease-free survival (HR=0.62; 95% CI: 0.41–0.95, p = 0.028). No association was found between D2–40 and VEGF-A expression and CC prognosis. Our data reinforces previous reports that suggest the potential use of CD31 as a CC prognostic biomarker. Additionally, our data further supports the evidence for an interplay between metabolic dysfunction, tumor microenvironment, and vascularization pathways.
Description
Keywords
Colon cancer Angiogenesis Lymphangiogenesis Metabolic syndrome Survival
Citation
Silva, A., Pereira, S. S., Brandão, J. R., Brochado, P., Monteiro, M. P., Araújo, A., & Faria, G. (2022). Colon tumor CD31 expression is associated with higher disease-free survival in patients with metabolic syndrome. Pathology - Research and Practice, 240, 154182. https://doi.org/10.1016/j.prp.2022.154182
Publisher
Elsevier